903
Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients.
 ( potential therapeutic event: administered ,  postmenopausal node-positive breast cancer patients: Subject, Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently: Treatment, tamoxifen: Treatment.Drug, Epirubicin-cyclophosphamide: Treatment.Drug, node-positive breast cancer: Treatment.Disorder, tamoxifen: Combination.Drug, Epirubicin-cyclophosphamide: Combination.Drug) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( potential therapeutic event: administered ,  postmenopausal node-positive breast cancer patients: Subject, Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently: Treatment, tamoxifen: Treatment.Drug, Epirubicin-cyclophosphamide: Treatment.Drug, node-positive breast cancer: Treatment.Disorder, tamoxifen: Combination.Drug, Epirubicin-cyclophosphamide: Combination.Drug) 